Jakob Lindberg was appointed CSO in 2023.
In addition to being CSO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, a part of Investor AB.
Jakob Lindberg was the CEO of Oncopeptides from the restart of the company in 2011, until June 2020, as well as from November 2021 until January 2023. During July 2020 until November 2021 he was the CSO of Oncopeptides. His previous roles include being an analyst at Merrill Lynch & Co and a consultant at McKinsey & Co. Jakob was co-founder of Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.
Jakob has studied medicine at the Karolinska Institute. He gained a Med Lic in Molecular Immunology and a MSc in pre-clinical medicine. He also has a BA in Finance and Administration from the Stockholm University.
Holdings in Oncopeptides: 868,331 shares (853,031 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 391,922 share awards* and 605,081 options*.
Other current positions: CEO of Oncopeptides, Inc, director of Oncopeptides Incentive AB, director of Affibody Medical AB and Lindberg Life-Science AB. CEO of Lindberg Life-Science AB.